Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, CanSino Biologics Inc.

Conditions

MeningitisMeningococcal InfectionsMeningococcal Meningitis

Phase 3

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

CompletedNCT06131554

CanSino Biologics Inc.Meningococcal Meningitis

Start: 2024-03-20End: 2025-06-04Updated: 2026-08-06

Phase 4

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

CompletedNCT02633787

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2015-12-31End: 2016-03-31Updated: 2016-11-07